Health
FDA approves new indication for drug to treat pediatric NDO patients – News-Medical.Net
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for…
Today, the U.S. Food and Drug Administration approved a new indication for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older. Myrbetriq is also indicated for overactive bladder in adult patients.
Today’s action is a positive step for the treatment of NDO in young patients. Mirabegron,…
-
General10 hours agoFarmers develop ‘autofill’ tech so agricultural robots can operate around the clock
-
Noosa News16 hours agoRevealed: 75 Qld suburbs you could afford to buy in if lending standards drop
-
General12 hours agoChoosing an online exercise program can be confusing. Here’s what to look out for
-
Noosa News15 hours agoNowhere is growing like this corner of Queensland. It’s changing the political game